Opportunities and challenges in the treatment of IgA nephropathy

TL;DR

This review discusses new treatment options and challenges in managing IgA nephropathy, a chronic kidney disease.

Contribution

The paper highlights emerging therapies and the need for personalized treatment strategies in IgA nephropathy.

Findings

New therapies like complement inhibitors and endothelin receptor antagonists show promise in IgAN treatment.

Combination therapies may offer greater benefits for IgAN patients.

Personalized precision therapy is a key challenge in IgAN management.

Abstract

The treatment paradigm of immunoglobulin A nephropathy (IgAN) is shifting, and traditional therapeutic strategies are insufficient to meet clinical needs. Based on the increasing understanding of the pathogenesis of IgAN, current treatment goals concentrate on anti-inflammatory and targeted therapy, as well as optimizing therapy. New therapeutic approaches are being developed, including complement inhibitors, B-cell activating factor and a proliferation-inducing ligand inhibitor, and endothelin receptor antagonists. Further supportive care showed promising prospects and combination therapy such as sodium-glucose cotransporter 2 inhibitor with endothelin receptor antagonists are also being investigated, which may provide greater benefit. IgAN is a disease that requires lifelong management, the treatment choices faced may be inconsistent at different ages and periods. With the emerging opportunities in IgAN treatment, achieving individualized precision therapy is a key challenge currently facing research institues. This review summarizes recent advances in the treatment of IgAN and discusses possible therapeutic strategies for IgAN patients.

Figures